Searched for:
(1 - 8 of 8)
document
Sugimoto-Kawabata, K. (author), Shimada, H. (author), Sakai, K. (author), Suzuki, K. (author), Kelder, T. (author), Pieterman, E.J. (author), Cohen, L.H. (author), Havekes, L.M. (author), Princen, H.M. (author), van den Hoek, A.M. (author)
Bile acid sequestrants (BASs) are cholesterollowering drugs that also affect hyperglycemia. The mechanism by which BASs exert these and other metabolic effects beyond cholesterol lowering remains poorly understood. The present study aimed to investigate the effects of a BAS, colestilan, on body weight, energy expenditure, and glucose and lipid...
article 2013
document
Liang, W. (author), Tonini, G. (author), Mulder, P. (author), Kelder, T. (author), van Erk, M. (author), van den Hoek, A.M. (author), Mariman, R. (author), Wielinga, P.Y. (author), Baccini, M. (author), Kooistra, T. (author), Biggeri, A. (author), Kleemann, R. (author)
Background:Chronic metabolic overload results in lipid accumulation and subsequent inflammation in white adipose tissue (WAT), often accompanied by non-alcoholic fatty liver disease (NAFLD). In response to metabolic overload, the expression of genes involved in lipid metabolism and inflammatory processes is adapted. However, it still remains...
article 2013
document
K├╝hnast, S. (author), van der Hoorn, J.W.A. (author), van den Hoek, A.M. (author), Havekes, L.M. (author), Liau, G. (author), Jukema, J.W. (author), Princen, H.M.G. (author)
Objective: Aliskiren is the first commercially available, orally active, direct renin inhibitor approved to treat hypertension. The renin-angiotensin system has been shown to be a significant contributor to the development of hypercholesterolemia-induced atherosclerosis. The aim of this study was to evaluate the antiatherosclerotic and plaque...
article 2012
document
Wei, H. (author), Hu, C. (author), Wang, M. (author), van den Hoek, A.M. (author), Reijmers, T.H. (author), Wopereis, S. (author), Bouwman, J. (author), Ramaker, R. (author), Korthout, H.A.A.J. (author), Vennik, M. (author), Hankemeier, T. (author), Havekes, L.M. (author), Witkamp, R.F. (author), Verheij, E.R. (author), Xu, G. (author), van der Greef, J. (author)
Background: Causes and consequences of the complex changes in lipids occurring in the metabolic syndrome are only partly understood. Several interconnected processes are deteriorating, which implies that multi-target approaches might be more successful than strategies based on a limited number of surrogate markers. Preparations from Chinese...
article 2012
document
Scully, M.S. (author), Ort, T.A. (author), James, I.E. (author), Bugelski, P.J. (author), Makropoulos, D.A. (author), Deutsch, H.A. (author), Pieterman, E.J. (author), van den Hoek, A.M. (author), Havekes, L.M. (author), Dubell, W.H. (author), Wertheimer, J.D. (author), Picha, K.M. (author)
Patients treated with recombinant human Epo demonstrate an improvement in insulin sensitivity. We aimed to investigate whether CNTO 530, a novel Epo receptor agonist, could affect glucose tolerance and insulin sensitivity. A single administration of CNTO 530 significantly and dose-dependently reduced the area under the curve in a glucose...
article 2011
document
Hu, C. (author), Wei, H. (author), van den Hoek, A.M. (author), Wang, M. (author), van der Heijden, R. (author), Spijksma, G. (author), Reijmers, T.H. (author), Bouwman, J. (author), Wopereis, S. (author), Havekes, L.M. (author), Verheij, E. (author), Hankemeier, T. (author), Xu, G. (author), van der Greef, J. (author)
Background: Lipids are known to play crucial roles in the development of life-style related risk factors such as obesity, dyslipoproteinemia, hypertension and diabetes. The first selective cannabinoid-1 receptor blocker rimonabant, an anorectic anti-obesity drug, was frequently used in conjunction with diet and exercise for patients with a body...
article 2011
document
Gaubius Instituut TNO (author), Coomans, C.P. (author), Geerling, J.J. (author), Guigas, B. (author), van den Hoek, A.M. (author), Parlevliet, E.T. (author), Ouwens, D.M. (author), Pijl, H. (author), Voshol, P.J. (author), Rensen, P.C.N. (author), Havekes, L.M. (author), Romijn, J.A. (author)
Insulin signaling in the central nervous system (CNS) is required for the inhibitory effect of insulin on glucose production. Our aim was to determine whether the CNS is also involved in the stimulatory effect of circulating insulin on the tissue-specific retention of fatty acid (FA) from plasma. In wild-type mice, hyperinsulinemic-euglycemic...
article 2011
document
TNO Kwaliteit van Leven (author), Kleemann, R. (author), van Erk, M. (author), Verschuren, L. (author), van den Hoek, A.M. (author), Koek, M. (author), Wielinga, P.Y. (author), Jie, A. (author), Pellis, L. (author), Bobeldijk-Pastorova, I. (author), Kelder, T. (author), Toet, K. (author), Wopereis, S. (author), Cnubben, N. (author), Evelo, C. (author), van Ommen, B. (author), Kooistra, T. (author)
BACKGROUND: The sequence of events leading to the development of insulin resistance (IR) as well as the underlying pathophysiological mechanisms are incompletely understood. As reductionist approaches have been largely unsuccessful in providing an understanding of the pathogenesis of IR, there is a need for an integrative, time-resolved approach...
article 2010
Searched for:
(1 - 8 of 8)